Comparing SG&A Expenses: Zoetis Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023.

Zoetis Inc.: A Steady Climb

Zoetis Inc., a leader in animal health, has seen its SG&A expenses grow by approximately 31% over the past decade, peaking at $2.15 billion in 2023. This steady increase reflects the company's strategic investments in marketing and administration to maintain its market dominance.

Amphastar Pharmaceuticals, Inc.: A Gradual Rise

Amphastar Pharmaceuticals, Inc., known for its innovative injectable and inhalation products, has experienced a 99% rise in SG&A expenses, reaching $80 million in 2023. This growth underscores Amphastar's commitment to expanding its market presence and operational capabilities.

Both companies demonstrate distinct financial strategies, with Zoetis focusing on sustained growth and Amphastar on rapid expansion.